{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:07:45Z","timestamp":1792019265324,"version":"4.4.0"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1001\/jamaoncol.2018.4604","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T22:33:47Z","timestamp":1543271627000},"page":"411","source":"Crossref","is-referenced-by-count":73,"title":["Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma"],"prefix":"10.1001","volume":"5","author":[{"given":"Saby","family":"George","sequence":"first","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Hammers","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, UT Southwestern, Kidney Cancer Program, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"crv180007r1","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/S1470-2045(09)70240-2","article-title":"Resistance to targeted therapy in renal-cell carcinoma.","volume":"10","author":"Rini","year":"2009","journal-title":"Lancet Oncol"},{"key":"crv180007r2","doi-asserted-by":"publisher","first-page":"284581","DOI":"10.1155\/2010\/284581","article-title":"Immunotherapy for renal cell carcinoma.","volume":"2010","author":"Itsumi","year":"2010","journal-title":"Clin Dev Immunol"},{"issue":"8","key":"crv180007r3","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.4161\/onci.21356","article-title":"Intratumoral alterations of dendritic-cell differentiation and CD8(+) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma.","volume":"1","author":"Noessner","year":"2012","journal-title":"Oncoimmunology"},{"key":"crv180007r4","first-page":"S55","article-title":"Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.","volume":"6","author":"Fisher","year":"2000","journal-title":"Cancer J Sci Am"},{"issue":"3","key":"crv180007r5","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"issue":"3","key":"crv180007r6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1158\/1078-0432.CCR-14-1520","article-title":"The high-dose aldesleukin \u201cselect\u201d trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.","volume":"21","author":"McDermott","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"19","key":"crv180007r7","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma.","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"crv180007r8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3389\/fonc.2014.00385","article-title":"CTLA-4 and PD-1 pathway blockade: combinations in the clinic.","volume":"4","author":"Callahan","year":"2015","journal-title":"Front Oncol"},{"issue":"1","key":"crv180007r9","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.4049\/jimmunol.178.Supp.48.37","article-title":"Activity of anti-PD-1 in murine tumor models: role of \u201chost\u201d PD-L1 and synergistic effect of anti-PD-1 and anti-CTLA-4","volume":"178","author":"Korman","year":"2007","journal-title":"J Immunol"},{"issue":"15","key":"crv180007r10","article-title":"Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models","volume":"31","author":"Selby","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"crv180007r11","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"crv180007r12","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri3064","article-title":"The parallel lives of angiogenesis and immunosuppression: cancer and other tales.","volume":"11","author":"Motz","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"crv180007r13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fonc.2015.00202","article-title":"Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data.","volume":"5","author":"Ott","year":"2015","journal-title":"Front Oncol"},{"issue":"1","key":"crv180007r14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s12307-014-0160-8","article-title":"Immune effects of bevacizumab: killing two birds with one stone.","volume":"8","author":"Elamin","year":"2015","journal-title":"Cancer Microenviron"},{"issue":"6","key":"crv180007r15","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/leu.2011.24","article-title":"Immunomodulatory effects of anti-angiogenic drugs.","volume":"25","author":"Heine","year":"2011","journal-title":"Leukemia"},{"issue":"7","key":"crv180007r16","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma.","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"385","key":"crv180007r17","doi-asserted-by":"publisher","first-page":"eaak9679","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.","volume":"9","author":"Allen","year":"2017","journal-title":"Sci Transl Med"},{"issue":"385","key":"crv180007r18","doi-asserted-by":"publisher","first-page":"eaak9670","DOI":"10.1126\/scitranslmed.aak9670","article-title":"Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.","volume":"9","author":"Schmittnaegel","year":"2017","journal-title":"Sci Transl Med"},{"issue":"34","key":"crv180007r19","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study.","volume":"35","author":"Hammers","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15","key":"crv180007r21","article-title":"IMmotion150: a phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun)","volume":"35","author":"Atkins","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"crv180007r22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"crv180007r23","first-page":"2622","article-title":"A phase 1\/2 study to assess the safety and efficacy of pazopanib and pembrolizumab in patients with advanced renal cell carcinoma","volume":"51","author":"McDermott","year":"2015","journal-title":"Eur J Cancer"},{"issue":"15","key":"crv180007r24","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1200\/JCO.2017.35.15_suppl.4506","article-title":"A phase I\/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC)","volume":"35","author":"Chowdhury","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"crv180007r25","doi-asserted-by":"publisher","first-page":"v295","DOI":"10.1093\/annonc\/mdx026","article-title":"A phase 1b\/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma.","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"crv180007r26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"crv180007r27","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1200\/JCO.2018.36.6_suppl.618","article-title":"Tivozanib combined with nivolumab: phase Ib\/II study in metastatic renal cell carcinoma (mRCC).","volume":"36","author":"Escudier","year":"2018","journal-title":"J Clin Oncol"},{"issue":"14","key":"crv180007r29","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"crv180007r31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade.","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"crv180007r32","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"crv180007r33","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma.","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"crv180007r34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"1","key":"crv180007r35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"13","key":"crv180007r36","doi-asserted-by":"publisher","first-page":"CT081","DOI":"10.1158\/1538-7445.AM2017-CT081","article-title":"Molecular correlates of differential response to atezolizumab +\/- bevacizumab vs sunitinib in a phase II study in untreated metastatic renal cell carcinoma (RCC) patients","volume":"77","author":"McDermott","year":"2017","journal-title":"Cancer Res"},{"issue":"12","key":"crv180007r37","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"issue":"17","key":"crv180007r38","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline.","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"14","key":"crv180007r39","doi-asserted-by":"publisher","first-page":"272","DOI":"10.21037\/atm","article-title":"Toxicity management of immunotherapy for patients with metastatic melanoma.","volume":"4","author":"Linardou","year":"2016","journal-title":"Ann Transl Med"},{"issue":"4","key":"crv180007r40","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.4143\/crt.2015.464","article-title":"A pilot study evaluating steroid-induced diabetes after antiemetic dexamethasone therapy in chemotherapy-treated cancer patients.","volume":"48","author":"Jeong","year":"2016","journal-title":"Cancer Res Treat"},{"issue":"28","key":"crv180007r41","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center.","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"issue":"21","key":"crv180007r43","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"issue":"34","key":"crv180007r44","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials.","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"crv180007r45","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1634\/theoncologist.2015-0151","article-title":"The association between PD-L1 expression and the clinical outcomes to vascular endothelial growth factor-targeted therapy in patients with metastatic clear cell renal cell carcinoma.","volume":"20","author":"Shin","year":"2015","journal-title":"Oncologist"},{"issue":"15","key":"crv180007r47","article-title":"Treatment-free survival (TFS), a novel outcome applied to immuno-oncology (IO) agents in advanced melanoma (AM)","volume":"36","author":"Regan","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"crv180007r48","doi-asserted-by":"publisher","first-page":"e16561","DOI":"10.1200\/JCO.2018.36.15_suppl.e16561","article-title":"Comparison of adverse event costs of nivolumab combined with ipilimumab versus sunitinib for previously untreated metastatic renal cell carcinoma","volume":"36","author":"Betts","year":"2018","journal-title":"J Clin Oncol"},{"key":"crv180007r20","author":"Amin","year":"2017"},{"key":"crv180007r28","author":"Motzer","year":"2017"},{"key":"crv180007r30","author":"Motzer","year":"2018"},{"key":"crv180007r42","author":"Santini","year":"2017"},{"key":"crv180007r46","author":"Atkins","year":"2017"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamaoncology\/article-pdf\/5\/3\/411\/17345826\/jamaoncology_george_2018_rv_180007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T15:05:32Z","timestamp":1694099132000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.4604"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.4604","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3,1]]}}}